Retatrutide

An investigational triple agonist. Phase 2 weight-change data exist in a peer-reviewed paper. It is not FDA-approved. Company toplines from TRIUMPH-2 and TRIUMPH-3 are not papers, and a planned BLA is not an approval. A research listing that shares the name is not the investigational product.

An investigational agonist at GIP, GLP-1, and glucagon receptors. The glucagon arm is intended to increase energy expenditure; that is also why heart-rate and hepatic signals are watched in the originating trial. Those are mechanisms under study, not a labelled use.

Jastreboff et al. (2023; PMID 37366315) reported a phase 2, placebo-controlled trial in 338 adults. The primary endpoint was percentage change in body weight at 24 weeks. At 48 weeks, a secondary time point, least-squares mean change was −24.2% with the 12 mg weekly arm and −2.1% with placebo. Gastrointestinal events were the most common adverse events and were dose-related. Heart rate rose in a dose-dependent way, peaked at 24 weeks, and declined thereafter. On 23 July 2026 Eli Lilly announced topline results from TRIUMPH-2 and TRIUMPH-3 and said it planned a BLA in Q1 2027. Those statements are company communications. Peer-reviewed phase 3 papers are not out. This record does not treat the toplines as papers and does not move the status to approved.

Not FDA-approved. Available in trials, not as a labelled medicine. Lilly’s 23 July 2026 announcement described TRIUMPH-2 and TRIUMPH-3 as successful and a BLA planned for Q1 2027. That is a company plan, not a listing and not an approval. Insurance does not pay for an unapproved product. Research-chemical listings are not the investigational product.

Not a marketed medicine. Legitimate access is a clinical trial (TRIUMPH program and related studies) through a research site. There is no approved pharmacy product.

Same four pathways as the Sourcing guide.

Trials cover the investigational product. Insurance does not pay for an unapproved drug outside a protocol. Cash 'retatrutide' from a wellness clinic is not the trial product.

Research-chemical listings appeared as soon as the phase 2 paper did. Those vials are not LY3437943 from the sponsor. Identity, dose, and sterility are unknown.

Strand does not list vendors. See the grey market.

The phase 2 paper reported gastrointestinal adverse events and a dose-related heart-rate increase. There is no FDA label. Phase 2 adverse events are not a substitute for one. Long-term safety at scale is not established.

• Unapproved: no established risk-management plan for unsupervised use.
• Phase 2 showed GI effects and a dose-related heart-rate increase.
• Glucagon-arm unknowns (hepatic, lean-mass) are still being mapped in phase 3.

• Jastreboff et al., phase 2 · 2023 · N Engl J Med

  Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023. PMID 37366315. DOI 10.1056/NEJMoa2301972. n=338; primary endpoint at 24 weeks; 48-week 12 mg arm −24.2% vs −2.1%. PMID 37366315.

• Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline

  Company announcement, 23 July 2026. Topline results, not a peer-reviewed paper. Cited only to identify that fact. A planned BLA in Q1 2027 is not an approval.